Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 May 2021 | Story André Damons | Photo André Damons
Prof Magda Mulder, who has been the Head of the School of Nursing for the past 10 years, retired on 26 May after 41 years at the University of the Free State (UFS). “I was privileged to work this long. I do not know of any other academic of my age who is still in a permanent position. It is time now to go and make room for a younger generation to take the school forward.”

Looking back on a career spanning four decades at the University of the Free State (UFS) School of Nursing, Prof Magda Mulder, who retired as Head of the school at the end of May, had more highs than lows. Her last day was on 26 May 2021 – ending a career of 41 years. 

One such achievement that this dedicated nursing professional can be proud of, is helping to ensure that the School of Nursing was one of the first training schools in South Africa to complete its curriculum during a year marked by a hard lockdown due to the COVID-19 pandemic. 

“My years at the School of Nursing were wonderful and joyous. Things do happen, and not everything was sunshine and rainbows. However, the past 10 years have been especially good because of the people and the team I have worked with, our achievements, and all the things we have done that we can be proud of,” said Prof Mulder.

Her highlights 

Prof Mulder’s first task when she started working at the UFS in 1980, was to standardise all the basic clinical procedures in nursing. This was an enormous undertaking that later turned into a textbook, now in its fourth edition (2019). 
Among Prof Mulder’s many highlights – which included starting the first nursing simulation laboratory, becoming part of the Faculty of Health Sciences, and moving to the Idalia Loots Building – the biggest highlight was receiving the Atlantic Philanthropies grant of R16 million. 

“During this period, we established an Academy and started developing short learning programmes to generate third-stream income for the school. In total, 35 short learning programmes were developed, the Benedictus Kok Building (Nursing education facility) was renovated, and new simulation laboratories were installed. It was a wonderful experience, and we started using simulations as an innovative teaching strategy for our students. The school benefited a great deal from that grant,” said Prof Mulder proudly. 

Nursing not the first choice 

According to Prof Mulder, nursing was not her first choice as a career, as she wanted to study either plant or animal science. Due to a lack of funding, she had to choose between nursing and teaching to earn money and be independent. Nursing won. 

“I have never regretted it. These have been wonderful years. The university is a great place to work. There is never a dull moment, and you do not know what to expect next. It was white-water rafting: you must go, go, go with the stream, and I think this was my salvation. I was able to adjust and adapt despite my age. Holding on to your old beliefs does not work.” 

Prof Mulder spent 10 years as Head of the School of Nursing, starting in 2011. Prior to this, she was Programme Director. 

Time to leave
According to her, COVID-19 made her realise that it was time to leave and make room for new blood to take the school further. 

“I was privileged to work this long. I do not know of any other academic of my age who is still in a permanent position. That in itself is a privilege. But it is time now to go and make room for a younger generation to take the school forward,” said Prof Mulder. 

With COVID-19 came many challenges, and she realised that her team needed to make a 90 degree turn from face-to-face teaching to online teaching. 

“It was not easy, but we did it. We were one of the first training schools in South Africa to complete the year. We had to plan to make up for the hours lost due to COVID-19, and we did it by getting the students to work night shift. We had to obtain special permission from private hospitals to let our students work longer hours.” 

The pandemic was also her worst time at the university.  On returning to campus during the lockdown to help students finish their training, Prof Mulder felt the impact of the lockdown. “The campus was dead quiet with not a soul in sight. It was like a graveyard. This was the worst part for me. Usually, I can hear the students from my office, I hear their laughter, and I hear the excitement of graduation, the drums. However, there was nothing. It was as if the world had come to an end.”

Future of nursing

After 41 years, Prof Mulder still talks with passion about nursing and students. She is excited about the future of nursing, the students, and the work the UFS School of Nursing is doing to prepare students for their careers.  However, she is also deeply concerned about the profession she loves so dearly. 

“There is a tremendous shortage of nurses worldwide, and we came to realise this during COVID. There are simply not enough nurses, especially in specialisation areas such as critical care, theatre, primary health care, and forensic nursing. Currently, all those programmes have been phased out. “We are waiting for the South African Nursing Council (SANC) to approve our new curricula,” said Prof Mulder.   

What comes next? 
Retiring is a bittersweet moment. “It was many years of long hours, working during holidays, working over weekends, and then suddenly there is nothing. It is a new phase in my life, and I am looking forward. I am excited but also hesitant, as I don’t know what to expect from the future.”

“I will miss nursing; I will miss the academic environment. I am a dedicated type of person; the academic environment was my life. These are my friends. I am going to miss the friendships I made here. As an academic, you do not have time to make other friends, so colleagues become your academic friends, and later they become your academic family. I will miss my team. I have an amazing team.”

 

 


Final goodbyes
Prof Marianne Reid, Associate Professor: School of Nursing (worked with Prof Mulder at the UFS since 2005)



“What an honour and privilege to work with Prof Magda. What nurse would not want to have Prof Magda as a model in her profession? She was the same as a person. She made me feel safe as an employee precisely because she could identify and exploit my personal limitations and possibilities.”

“Prof Mulder was the type of leader who invited us to participate, and then gave her input by pointing out the pros and cons. May this new phase in your life be a blessing and be aware of the blessings from our Lord daily. May the prospect of big plans feature in the future.”


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept